letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...2223242526272829303132...100101»
  • ||||||||||  letrozole / Generic mfg.
    Review, Journal:  A Review on the Use of Letrozole in Female and Male Infertility. (Pubmed Central) -  Dec 16, 2022   
    According to the most recent research, letrozole can be used as the first-line therapy to treat infertility caused by polycystic ovarian syndrome and other causes. Letrozole is also emerging as a possible treatment for male infertility of unknown cause, proving to be an effective way of influencing hormonal profiles and increasing various seminal parameters such as sperm motility and concentration, as it inhibits aromatization affecting the feedback mechanism to the hypothalamus. This review focuses on our current knowledge of the uses of letrozole for female and male infertility, its mechanisms, and its benefits.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Role and mechanism of alpa1-antitrypsin in polycystic ovary syndrome. (Pubmed Central) -  Dec 16, 2022   
    Alpha1-antitrypsin is closely associated with NE, IL-1β, and IL-8. Therefore, we speculate that A1AT might ameliorate PCOS symptoms by inhibiting pro-inflammatory factors: NE, IL-1β, and IL-8.
  • ||||||||||  letrozole / Generic mfg.
    Clinical, Journal, HEOR:  Health-related quality of life in boys with constitutional delay of growth and puberty. (Pubmed Central) -  Dec 16, 2022   
    P2/3
    In terms of HRQoL, the main impact of delayed puberty was dissatisfaction with physical appearance. Puberty promoting therapy was associated with a positive change in perceived appearance, with no clear difference between low-dose testosterone and letrozole treatments.
  • ||||||||||  PF-07248144 / Pfizer
    Trial completion date, Trial primary completion date, Metastases:  C4551001: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) -  Dec 13, 2022   
    P1,  N=108, Recruiting, 
    As compared with D3 group, D5 group was associated with higher ovulation and conception rates, shorter time-to-pregnancy among infertile women with the PCOS. Trial completion date: Oct 2025 --> Sep 2027 | Trial primary completion date: May 2024 --> Apr 2026
  • ||||||||||  letrozole / Generic mfg., everolimus / Generic mfg.
    Enrollment change, Trial completion date, Metastases:  Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov) -  Dec 13, 2022   
    P2,  N=42, Active, not recruiting, 
    Trial completion date: Dec 2022 --> Nov 2024 | Trial primary completion date: Nov 2022 --> Nov 2024 N=31 --> 42 | Trial completion date: Apr 2022 --> Apr 2023
  • ||||||||||  metformin / Generic mfg., letrozole / Generic mfg.
    Preclinical, Journal:  Kelulut Honey Regulates Sex Steroid Receptors in a Polycystic Ovary Syndrome Rat Model. (Pubmed Central) -  Dec 12, 2022   
    The study used female Sprague-Dawley rats, which were treated orally with 1 mg/kg/day of letrozole for 21 days to develop PCOS...Hence, this study confirms the aberrant expression of sex steroid receptors in PCOS and demonstrates that KH treatment could normalise the sex steroid receptors profile. The findings provide a basis for future clinical trials to utilize KH as a regulator of sex steroid receptors in patients with PCOS.
  • ||||||||||  progesterone / Generic mfg., letrozole / Generic mfg.
    Preclinical, Journal:  Decoding the molecular cascade of embryonic-uterine modulators in pregnancy loss of PCOS mother- an "in vivo" study. (Pubmed Central) -  Dec 9, 2022   
    Asafoetida appears to act by regulating and activating metabolic and ovarian cycle enzymes. Our results reveal that majority of the molecular markers alteration in the establishment of early pregnancy could be due to the aberrant progesterone signaling in the embryonic-uterine tissue of PCOS animals, which further translates into poor fetal outcomes as observed in the current study and in several IVF patients.
  • ||||||||||  letrozole / Generic mfg.
    Retrospective data, Journal:  The earlier the initiation of gonadotropin in poor responders in luteal phase stimulation protocols, the better. (Pubmed Central) -  Dec 6, 2022   
    HMG and letrozole were administrated after ovulation...Meanwhile, there were no significant differences in the mean number of oocytes, utilizable embryos, pregnancy outcomes among three groups. Although the timing of gonadotropin initiation is not associated with pregnancy outcomes, earlier initiation of gonadotropin therapy after ovulation was associated with a shorter duration of ovarian stimulation and lower gonadotropin consumption in poor responders in LPS.
  • ||||||||||  letrozole / Generic mfg.
    Enrollment open:  Letrozole in Preventing Recurrence of Endometrioma Following Laparoscopic Ovarian Cystectomy (clinicaltrials.gov) -  Dec 2, 2022   
    P=N/A,  N=194, Recruiting, 
    In summary, genetically engineered mouse models of Esr1 and CYP19A1 overexpression revealed a diversion of disease processes resulting from the two distinct molecular pathophysiological mammary gland-targeted intrusions into estrogen signaling during reproductive senescence. Not yet recruiting --> Recruiting
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Probability of Pregnancy With Mono vs Multiple Folliculogenesis in Women With Unexplained Infertility. (Pubmed Central) -  Dec 1, 2022   
    When stratified by treatment modality, no association of follicle number with CPR or LBR was observed for letrozole or clomiphene, but women using gonadotropins had lower CPR and LBR with monofolliculogenesis. In couples undergoing gonadotropin treatment for UI, monofolliculogenesis following OS is related to a lower rate of live birth.
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  APPOSE: Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis (clinicaltrials.gov) -  Dec 1, 2022   
    P2,  N=60, Recruiting, 
    In couples undergoing gonadotropin treatment for UI, monofolliculogenesis following OS is related to a lower rate of live birth. Trial completion date: Mar 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> May 2023
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Agent-Based Models Help Interpret Patterns of Clinical Drug Resistance by Contextualizing Competition Between Distinct Drug Failure Modes. (Pubmed Central) -  Nov 30, 2022   
    The degree of resistance conferred by cancer associated fibroblasts in the tumor microenvironment was quantified by treating mono- and co-cultures with letrozole and then measuring the death rates...Our model results demonstrate that spatial effects can interact with low magnitude of resistance microenvironmental effects to successfully compete against genetic resistance that is orders of magnitude larger. Clinical outcomes of solid tumors are intrinsically connected to their spatial structure, and the tractability of spatial agent-based models like the ones presented here enable us to understand this relationship more completely.
  • ||||||||||  letrozole / Generic mfg.
    Enrollment change, Trial withdrawal:  Different Protocols in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles (clinicaltrials.gov) -  Nov 30, 2022   
    P=N/A,  N=0, Withdrawn, 
    Clinical outcomes of solid tumors are intrinsically connected to their spatial structure, and the tractability of spatial agent-based models like the ones presented here enable us to understand this relationship more completely. N=100 --> 0 | Unknown status --> Withdrawn
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Modified Cangfu Daotan decoction ameliorates polycystic ovary syndrome with insulin resistance via NF-κB/LCN-2 signaling pathway in inflammatory microenvironment. (Pubmed Central) -  Nov 29, 2022   
    We used a high-fat diet (42 days) combined with letrozole (1 mg/kg/day, 42 days) to establish a PCOS-IR rat model...Our results showed that MCDD could reduce body weight and abdominal fat weight; restore normal estrous cycle and ovarian function; alleviate fatty liver; regulate HOMA-IR and OGTT index; reduce serum inflammatory factor levels, LCN-2 level, and gene expression; and regulate the insulin signal transduction and NF-κB pathways in PCOS-IR rats. Thus, MCDD may play a role in improving ovarian function in PCOS-IR rats by downregulating NF-κB/LCN-2 proteins and upregulating the gene expression of Insr/Irs-1/Glut4 in the insulin signaling pathway in the inflammatory environment.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Letrozole treatment alters hippocampal gene expression in common marmosets (Callithrix jacchus). (Pubmed Central) -  Nov 27, 2022   
    Based on the transcriptional changes observed, we conclude that AIs may differentially affect the sexes in part due to processes mediated by the CYP-450 superfamily. Ongoing studies will further investigate the longitudinal effects of AIs on behavior and whether AIs increase the risk of stress-induced neurodegeneration.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Effect of Flax lignans on apoptosis of growth plate chondrocytes in rats (Pubmed Central) -  Nov 24, 2022   
    The appropriate concentration of linseed lignans can significantly inhibit the apoptosis of chondrocytes in the growth plate of rats, and the optimal drug concentration is 20 μM. It provides possibility for delayed bone closure and longer growth time to promote bone growth during development.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Breast cancer management with CDK4/6 inhibitors as first line treatment: a single institution retrospective review (Exhibition Hall) -  Nov 23, 2022 - Abstract #EBCC2022EBCC_464;    
    With a median fup of 20mo we found a median PFS in ET sensitive and ET resistant population similar to pooled median PFS of randomized controlled trials (RCTs) and Real world data already published. Dose reduction (59,8%) and CDK4/6i discontinuation rate due to toxicity (12,8%) were slightly higher than those in the RCTs (31-55% and 4-10% respectively).
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Abemaciclib for treating patients with HR+, HER2- advanced/metastatic breast cancer in Spain: a real-world study (Exhibition Hall) -  Nov 23, 2022 - Abstract #EBCC2022EBCC_366;    
    Abemaciclib, used in different lines of treatment and mostly in combination with AIs or fulvestrant, in a real-world setting in patients with HR+, HER2- ABC/MBC in Spain, was associated with a median PFS of 21.5 months and complete or partial response of 42.8%. These data are comparable to data from clinical trials supporting the benefit of abemaciclib for patients with HR+, HER2- ABC/MBC.